Nykredit A S Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Nykredit A S purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 51,208 shares of the biopharmaceutical company’s stock, valued at approximately $15,415,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $895,816,000. Legal & General Group Plc purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $278,321,000. Qube Research & Technologies Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $369,943,000. AQR Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after purchasing an additional 555,759 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $148,128,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $266.11 on Friday. The firm has a 50 day moving average of $259.25 and a 200-day moving average of $291.61. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The company has a market cap of $35.61 billion, a price-to-earnings ratio of 49.46 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.51) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target for the company in a report on Monday, August 3rd. JPMorgan Chase & Co. decreased their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Bank of America dropped their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Finally, Oppenheimer cut their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.